This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against Amarin Corp. Plc And Its Board Of Directors And Of A Lead Plaintiff Deadline Of January 3, 2014

NEW YORK, Dec. 24, 2013 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Amarin Corp. plc ("Amarin" or the "Company") (NasdaqGM: AMRN) common stock between July 9, 2009 and October 15, 2013.

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO)

For more information, click here: http://zlk.9nl.com/amarin-corp-amrn/.

The complaint alleges that Defendants made false and/or misleading statements regarding the likelihood that its drug Vascepa would be approved by the Food and Drug Administration for the ANCHOR indication. It is further alleged that Amarin failed to disclose that the FDA had informed the Company there was a lack of prospective, controlled clinical trial data that pharmaceutical reduction of triglycerides significantly reduces residual cardiovascular risk.

On October 11, 2013, Amarin shares fell more than 20% to close at $5.09 after the FDA released its briefing documents for the October 16, 2013 advisory committee review of Amarin's application to expand the use of its drug Vascepa. The FDA briefing documents raised questions about the mineral oil placebo potentially negatively impacting the control group data and consequentially overstating Vascepa's effectiveness. Then on October 30, 2013, Amarin disclosed that the FDA had rescinded the ANCHOR study special protocol assessment agreement. Shares of Amarin closed at $1.64 per share on November 1, 2013.

If you suffered a loss in Amarin you have until January 3, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/amarin-corp-amrn/.  

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C.  The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:     Levi & Korsinsky, LLP Joseph Levi, Esq. Eduard Korsinsky, Esq.30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500Toll Free:  (877) 363-5972Fax: (212) 363-7171 www.zlk.com

SOURCE Levi & Korsinsky, LLP

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs